Current and future antiplatelet therapies: emphasis on preserving haemostasis
JD McFadyen, M Schaff, K Peter - Nature Reviews Cardiology, 2018 - nature.com
Antiplatelet drugs, such as aspirin, P2Y12 antagonists, and glycoprotein (GP) IIb/IIIa
inhibitors, have proved to be successful in reducing the morbidity and mortality associated …
inhibitors, have proved to be successful in reducing the morbidity and mortality associated …
Integrins as therapeutic targets: lessons and opportunities
The integrins are a large family of cell adhesion molecules that are essential for the
regulation of cell growth and function. The identification of key roles for integrins in a diverse …
regulation of cell growth and function. The identification of key roles for integrins in a diverse …
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a …
Background—Aspirin and clopidogrel are recommended for patients with acute coronary
syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible oral P2Y12 …
syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible oral P2Y12 …
Antiplatelet agents for the treatment and prevention of atherothrombosis
C Patrono, F Andreotti, H Arnesen… - European heart …, 2011 - academic.oup.com
The clinical pharmacology of antiplatelet drugs has been reviewed previously by the
European Society of Cardiology (ESC) Task force and by the 8th American College of Chest …
European Society of Cardiology (ESC) Task force and by the 8th American College of Chest …
The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes
Platelets are causally involved in coronary artery obstruction in acute coronary syndromes
(ACS). This cell type is unique to mammals and its production, which is unlike that of any …
(ACS). This cell type is unique to mammals and its production, which is unlike that of any …
αvβ3‐or α5β1‐integrin‐selective peptidomimetics for surface coating
C Mas‐Moruno, R Fraioli… - Angewandte Chemie …, 2016 - Wiley Online Library
Engineering biomaterials with integrin‐binding activity is a very powerful approach to
promote cell adhesion, modulate cell behavior, and induce specific biological responses at …
promote cell adhesion, modulate cell behavior, and induce specific biological responses at …
" Venomous" Bites from" non-venomous" Snakes
SA Weinstein, DA Warrell, DE Keyler - 2022 - books.google.com
" Venomous" Bites from" Non-Venomous" Snakes, Second Edition thoroughly examines the
potential hazards associated with bites by non-front-fanged snakes (popularly, but …
potential hazards associated with bites by non-front-fanged snakes (popularly, but …
Lipoproteins as modulators of atherothrombosis: from endothelial function to primary and secondary coagulation
AB Ouweneel, M Van Eck - Vascular pharmacology, 2016 - Elsevier
Atherothrombosis is a complication of atherosclerosis that causes acute cardiovascular
events such as myocardial infarction and stroke. Circulating lipid levels are highly correlated …
events such as myocardial infarction and stroke. Circulating lipid levels are highly correlated …
Updates to the ACCF/AHA and ESC STEMI and NSTEMI guidelines: putting guidelines into clinical practice
JD Wessler, J Stant, S Duru, LR Rabbani… - American Journal of …, 2015 - ajconline.org
The publication of consensus group guidelines provides an opportunity to standardize
practices through evidence-based protocols. Variations in patient care have been shown to …
practices through evidence-based protocols. Variations in patient care have been shown to …
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta …
AM Rafique, P Nayyar, TY Wang, R Mehran… - JACC: Cardiovascular …, 2016 - jacc.org
Objectives: The study sought to compare the clinical efficacy and safety of P2Y12 inhibitors
in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary …
in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary …